Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5272430 | 0.83 | ALDH1A1 (0.46) | PTGS2ALDH1A1GAAKDM4EHPGD | |
| SCHEMBL14612615 | 0.82 | KMT2A (0.54) | PTGS2ALDH1A1GAAKDM4EHPGD | |
| SCHEMBL1541914 | 0.80 | ACHE (0.59) | PTGS2ALDH1A1GAAKDM4EHPGD | |
| SCHEMBL12636264 | 0.80 | DHFR (0.42) | PTGS2ALDH1A1KDM4EHPGDCYP1A2 | |
| SCHEMBL22173564 | 0.79 | SLC6A4 (0.50) | ALDH1A1GAAKDM4ECYP1A2 | |
| SCHEMBL5275708 | 0.79 | CYP1A2 (0.67) | GAACYP1A2TAAR1 | |
| SCHEMBL5272609 | 0.79 | KMT2A (0.45) | PTGS2ALDH1A1GAAKDM4EHPGD | |
| SCHEMBL13888758 | 0.78 | ERN1 (0.56) | PTGS2ALDH1A1GAAKDM4EERN1 | |
| SCHEMBL14612616 | 0.78 | KMT2A (0.37) | PTGS2ALDH1A1GAACYP1A2TAAR1 | |
| SCHEMBL14612683 | 0.78 | CA2 (0.41) | PTGS2ALDH1A1GAAHPGDCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | CCR3, CCR1, CCR4 | PTGS2 997/4885ALDH1A1 451/4885GAA 3437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.